Alnylam Pharmaceuticals
ALNY
#591
Rank
NZ$58.40 B
Marketcap
$452.78
Share price
-0.29%
Change (1 day)
57.92%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of November 2024 (TTM): 16.8

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is > 1000. At the end of 2024 the company had a P/S ratio of 16.8.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2024

PS ratio at the end of each year

Year P/S ratio Change
202416.828.24%
202313.1-53.38%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
135 707.44%๐Ÿ‡บ๐Ÿ‡ธ USA
6.54-60.96%๐Ÿ‡บ๐Ÿ‡ธ USA
7.64-54.40%๐Ÿ‡บ๐Ÿ‡ธ USA
1.40-91.64%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
4.29-74.42%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
2.45-85.39%๐Ÿ‡ซ๐Ÿ‡ท France
1.22-92.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel